Human biological sample biobanking to support tissue biomarkers in pharmaceutical research and development

Methods. 2014 Nov;70(1):3-11. doi: 10.1016/j.ymeth.2014.01.014. Epub 2014 Jan 30.

Abstract

Advances in the understanding of molecular pathology and thereby the mechanisms that could be amenable to therapeutic manipulation are the reason that pharmaceutical research and development is focused increasingly on measurement of molecular biomarkers in human biological samples. Obtaining direct or indirect access to sufficient samples that are fit for research purposes can be a major challenge. A biobanking infrastructure has a significant role in the acquisition, storage and usage of human biological samples and here we review some key requirements for establishing a biobank. These include ensuring; that appropriate governance mechanisms are in place, that samples available are appropriate and fit for the intended research purposes that the infrastructure is sustainable in the future and that use of the biobank assets meets the strategic aims of the host organisation. Finally we present a case study--the STRATUM project which has recently completed and through a collaborative approach involving six industry and public partners drawing on a network of experts, examined biobank policies, public attitudes to biobanking, donor consent, sample and data standards, technical requirements for a register and biobanking financial models, albeit from a UK perspective.

Keywords: Biobanking; Drug discovery; Governance; Human biological samples; Molecular pathology; Quality.

Publication types

  • Review

MeSH terms

  • Biological Specimen Banks / ethics
  • Biological Specimen Banks / trends*
  • Biomarkers / metabolism*
  • Biomedical Research / ethics
  • Biomedical Research / trends
  • Chemistry, Pharmaceutical / methods*
  • Drug Industry
  • Ethics, Medical
  • Humans
  • Pathology, Molecular
  • Precision Medicine / ethics
  • Precision Medicine / trends
  • Tissue Donors

Substances

  • Biomarkers